Eiger Biopharmaceuticals (NASDAQ:EIGR) Releases Earnings Results, Misses Estimates By $0.01 EPS

Eiger Biopharmaceuticals (NASDAQ:EIGR) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.76) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.75) by ($0.01), Fidelity Earnings reports.

EIGR stock traded up $0.17 during mid-day trading on Friday, reaching $10.97. The company had a trading volume of 128,400 shares, compared to its average volume of 155,450. The company has a debt-to-equity ratio of 0.36, a current ratio of 9.64 and a quick ratio of 9.64. The stock has a 50 day simple moving average of $10.63 and a two-hundred day simple moving average of $10.76. The company has a market capitalization of $275.02 million, a price-to-earnings ratio of -2.87 and a beta of 1.02. Eiger Biopharmaceuticals has a 52 week low of $8.40 and a 52 week high of $15.33.

A number of research analysts recently issued reports on EIGR shares. BidaskClub upgraded Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, October 30th. LADENBURG THALM/SH SH reiterated a “buy” rating and set a $28.00 price objective on shares of Eiger Biopharmaceuticals in a report on Monday, August 12th. Finally, Zacks Investment Research upgraded Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a report on Tuesday, August 13th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $28.67.

About Eiger Biopharmaceuticals

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

Recommended Story: What is quantitative easing?

Earnings History for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply